文献速递青光眼神经眼科

SARM1调控SNPH表达参与青光眼视神经病变的机制研究

[Regulation of SARM1 on SNPH expression and its participation in glaucomatous optic neuropathy].
PubMed 文献 · Zhonghua Yan Ke Za Zhi · 2026-01-01

该实验研究在大鼠慢性高眼压青光眼模型中检测SARM1与SNPH在视网膜和视神经的表达变化,并在661W细胞中通过CRISPR/Cas9敲低验证二者调控关系。结果显示造模后1周视神经SARM1表达升高、SNPH在3天降低后1周回升,敲低SARM1可降低SNPH表达。

要点

  • 大鼠青光眼模型造模后1周视神经SARM1蛋白表达高于对照组。
  • 视网膜SNPH在造模后3天低于对照组,1周时高于3天。
  • 661W细胞敲低SARM1可降低SNPH表达,提示SARM1调控SNPH。

核心结论

  • 大鼠青光眼模型中视神经轴突SARM1蛋白表达升高,通过定位于轴突线粒体并调控SNPH表达,参与视网膜神经节细胞轴突病变。

研究设计与样本

  • 实验研究,2024年2月至2025年10月开展,8~10周龄雄性Wistar大鼠每组6只,均取右眼纳入实验。
  • 模型组前房注射微粒磁珠构建慢性高眼压青光眼模型,对照组前房注射等体积生理盐水,于造模后3天、1周和2周取材。
  • 采用TonoLab眼压计测眼压,视网膜铺片Brn3A免疫荧光检测RGC丢失,Western印迹和免疫荧光检测SARM1与SNPH表达及分布。
  • 利用CRISPR/Cas9技术分别敲低小鼠661W视网膜神经节细胞系中SARM1和SNPH,转染48小时后收集细胞行Western印迹检测。

主要发现

  • 模型组造模后1周视神经SARM1蛋白相对表达量(1.22±0.06)高于对照组(1.03±0.01,P=0.027,q=4.38)。
  • 模型组造模后3天视网膜SARM1蛋白表达量(0.79±0.02)低于对照组(1.04±0.03,P<0.001,q=6.86)。
  • SNPH表达量在造模后3天(0.74±0.01)低于对照组(1.03±0.04,P=0.040,q=0.58),造模后1周(1.19±0.10)高于造模后3天(0.74±0.01,P=0.002,q=4.36)。
  • 免疫荧光显示模型组视神经SARM1在造模后1周高于对照组,SNPH在造模后3天低于对照组,两种蛋白与β3-tubulin部分共定位并在轴突中共定位,SARM1与TOM20共定位。
  • 661W细胞中敲低SARM1(0.54±0.04)可降低SNPH表达(0.54±0.05,P=0.003,q=7.98),敲低SNPH(0.39±0.06)对SARM1表达影响较小(0.75±0.05,P=0.010,q=6.39)。

临床怎么用

  • 该研究提示SARM1-SNPH轴可能是青光眼视神经病变的潜在分子干预靶点,但尚属动物与细胞实验阶段,未提供临床诊疗推荐。

局限性

  • 研究仅使用大鼠模型和小鼠661W细胞系,样本量小(每组6只动物),未涉及人体组织或临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the molecular mechanism of toll-like receptor adaptor protein SARM1 in glaucomatous optic neuropathy. Methods: The experimental study was conducted from February 2024 to October 2025. A chronic ocular hypertension glaucoma model was established by injecting micro-magnetic beads into the anterior chamber of 8- to 10-week-old male Wistar rats. At 3 days, 1 week, and 2 weeks post-modeling, retinal and optic nerve tissues from 6 eyes of 6 rats were collected as the chronic ocular hypertension glaucoma model group, and 6 eyes from 6 wild-type rats that received an equal volume of saline via anterior chamber injection served as the control group. Intraocular pressure was measured using a TonoLab tonometer. Retinal whole-mounts were prepared and POU domain class 4 transcription factor 1 (POU4F1 or Brn3A) immunofluorescence staining was used to detect retinal ganglion cell loss. Western blotting was performed to detect the expression levels of SARM1 and SNPH in the rat retina and optic nerve. Immunofluorescence staining was used to examine their distribution in these tissues. Furthermore, CRISPR/Cas9 technology was used to knock down the expression of SARM1 and SNPH in mouse 661W retinal ganglion cells, respectively. Cells were collected 48 hours after transfection, and Western blotting was performed to detect the expression levels of SARM1 and SNPH. Normally distributed continuous data are presented as mean±SEM. Comparisons between two groups were performed using the Student's t-test, while comparisons among multiple groups were assessed by the one-way analysis of variance followed by the Tukey's multiple comparisons test. Results: Western blot analysis revealed that in the glaucoma model group, the relative expression level of SARM1 protein in the optic nerve at one week post-modeling (1.22±0.06) was significantly higher than that in the control group (1.03±0.01; P=0.027, q=4.38). In contrast, the expression level of SARM1 in the retina at three days post-modeling (0.79±0.02) was significantly lower than that in the control group (1.04±0.03; P<0.001, q=6.86). Concurrently, the expression level of SNPH at three days post-modeling (0.74±0.01) was lower than that in the control group (1.03±0.04; P=0.040, q=0.58), and its expression at one week post-modeling (1.19±0.10; P=0.002, q=4.36) was significantly higher than that at three days (0.74±0.01). Consistent with the Western blot results, immunofluorescence staining results showed that in the optic nerve of the glaucoma model group, the expression of SARM1 was significantly higher than that in the control group at one week post-modeling, while the expression of SNPH was lower than that in the control group at three days post-modeling. Both proteins partially co-localized with the neuronal marker β3-tubulin. Immunofluorescence staining also revealed co-localization of these two proteins within axons. Additionally, SARM1 co-localized with the mitochondrial marker protein TOM20. Western blot results from 661W cells showed that the knockdown of SARM1 expression (0.54±0.04) significantly reduced SNPH expression (0.54±0.05; P=0.003, q=7.98), whereas the knockdown of SNPH expression (0.39±0.06) did not markedly affect SARM1 levels (0.75±0.05; P=0.010, q=6.39). Conclusion: The elevated expression of SARM1 protein in the axons of the rat glaucoma model can promote retinal ganglion cell axonal pathology by localizing to axonal mitochondria and regulating SNPH expression. 目的: 探讨Toll样受体适配蛋白含无菌α基序及Toll/白介素受体基序蛋白1(SARM1)调控轴突线粒体锚定蛋白(SNPH)表达参与青光眼视神经病变的机制。 方法: 实验研究,于2024年2月至2025年10月开展。用简单随机法将8~10周Wistar雄性大鼠分为对照组和青光眼模型组,每组6只动物,均取右眼纳入实验。模型组进行前房微粒磁珠注射,构建慢性高眼压青光眼模型,在造模后3 d、1周和2周取视网膜和视神经进行实验;对照组大鼠前房注射等体积生理盐水。使用TonoLab眼压计测量大鼠眼压。采用视网膜铺片Brn3A免疫荧光染色检测视网膜神经节细胞(RGC)丢失情况。采用Western印迹检测大鼠视网膜和视神经中SARM1和SNPH的表达情况。采用免疫荧光染色法检测大鼠SARM1和SNPH在视网膜和轴突中的表达分布情况。并利用成簇规律间隔短回文重复序列(CRISPR)/核酸内切酶9(Cas9)技术分别降低小鼠视网膜神经节细胞系661W中SARM1和SNPH的表达,转染48 h后收集细胞。采用Western印迹检测细胞中SARM1和SNPH的表达情况。采用独立样本t检验、单因素方差分析、Tukey多重比较进行统计学分析。 结果: Western印迹结果显示,模型组造模后1周,视神经中的SARM1蛋白的相对表达量(1.22±0.06)高于对照组(1.03±0.01,P=0.027,q=4.38)。而视网膜中SARM1蛋白表达量在造模后3 d(0.79±0.02)低于对照组(1.04±0.03,P<0.001,q=6.86)。SNPH的表达量在造模后3 d(0.74±0.01)低于对照组(1.03±0.04,P=0.040,q=0.58),并在造模后1周(1.19±0.10,P=0.002,q=4.36)表达量高于造模后3 d(0.74±0.01)。免疫荧光染色结果显示,模型组RGC轴突中SARM1的表达在造模后1周高于对照组,SNPH的表达在造模后3 d低于对照组与Western印迹结果一致。并且都与神经元标志物微管蛋白部分共定位。并且免疫荧光染色结果还显示这两种蛋白在视神经中共定位。SARM1与线粒体标志物蛋白TOM20共定位。661W细胞中Western印迹结果显示,SARM1表达降低(0.54±0.04)可降低SNPH(0.54±0.05,P=0.003,q=7.98)的表达,但SNPH表达降低(0.39±0.06)对SARM1表达影响较小(0.75±0.05,P=0.010,q=6.39)。 结论: SARM1蛋白在大鼠青光眼模型组中的视神经中表达升高,通过定位于线粒体调控SNPH表达参与RGCs视神经病变。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhang XJ, Wu JH. [Regulation of SARM1 on SNPH expression and its participation in glaucomatous optic neuropathy]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42379865. doi:10.3760/cma.j.cn112142-20251106-00463

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。